. Author manuscript; available in PMC: 2018 Mar 1.

Published in final edited form as: J Allergy Clin Immunol. 2016 Sep 5;139(3):882–888.e5. doi: 10.1016/j.jaci.2016.07.030

Table 1.

Baseline Characteristics and Duration of Therapy for all subjects (N=104). Summary statistics above are either counts (percentage) or medians (first and third quartiles).

Females	39 (38%)
Age at Starting OIT (years)
0–3	57 (55%)
4–7	39 (38%)
8–13	8 (8%)
Race
White	92 (88%)
Black	6 (6%)
Other	6 (6%)
History of Asthma	46 (44%)
History of Atopic Dermatitis	80 (77%)
History of Allergic Rhinitis	48 (46%)
Peanut Skin Prick Test (mm)	13 (9, 17)
Peanut IgE (kU/L)	55 (17, 189)
Peanut IgG4 (kU/L)	0.4 (0.1, 0.8)
Days on Therapy	1012 (712, 1443)
Days in Buildup Phase	314 (236, 351)
Days in Maintenance Phase^*	570 (327, 1137)

for those who made it to the maintenance phase (n=87).